Xeris Biopharma Holdings

XERS

Market cap $1.19B

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 Earnings Conference Call.

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by increased patient demand across all three products,” said John Shannon, Chief Executive Officer. “Total product revenue grew 4.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.

Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 382,975 shares of its common stock to 40 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equit.

Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.